ACRS
HealthcareAclaris Therapeutics, Inc. · Biotechnology · $550M
What is Aclaris Therapeutics, Inc.?
Aclaris Therapeutics is a clinical-stage biopharmaceutical company headquartered in Wayne, Pennsylvania, focused on developing treatments for immune-inflammatory diseases.
Aclaris operates through two segments: Therapeutics and Contract Research. The Therapeutics segment advances novel drug candidates targeting conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and inflammatory bowel disease. The Contract Research segment provides laboratory services, offering a secondary revenue stream while the pipeline matures.
Aclaris Therapeutics was incorporated in 2012 and is based in Wayne, Pennsylvania.
- Zunsemetinib — an MK2 inhibitor for rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa
- ATI-1777 — a soft JAK 1/3 inhibitor for moderate to severe atopic dermatitis
- ATI-2138 — an ITK/TXK/JAK3 inhibitor targeting T cell-mediated autoimmune diseases
- Contract laboratory research services
Is ACRS a Good Stock to Buy?
UQS Score rates ACRS as Poor overall.
Among the five pillars, Risk stands out as the relative bright spot, suggesting the company carries a more manageable near-term risk profile than its overall score implies.
Quality, Moat, and Growth all register as Weak, reflecting the early-stage nature of the pipeline, while Valuation is rated Elevated — a challenging combination for investors.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ACRS pay dividends?
No — Aclaris Therapeutics, Inc. does not currently pay a dividend.
Aclaris does not pay a dividend. As a clinical-stage company, capital is directed toward research, development, and advancing its pipeline candidates through clinical trials rather than returned to shareholders as income.
When does ACRS report earnings?
Aclaris Therapeutics reports earnings on a quarterly cadence, typical for US-listed equities.
As a clinical-stage company, quarterly results are driven largely by research spending and contract research revenue rather than product sales. Pipeline milestones and trial readouts tend to be more closely watched than traditional earnings metrics.
For the most recent quarter's results, visit Aclaris Therapeutics' investor relations page.
ACRS Price History
-81.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Aclaris Therapeutics, Inc.?
Based on Aclaris Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Aclaris Therapeutics do?
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for immune-inflammatory diseases, including rheumatoid arthritis, atopic dermatitis, and inflammatory bowel disease. It also runs a Contract Research segment that provides laboratory services.
Does ACRS pay dividends?
No, ACRS does not pay a dividend. The company reinvests available capital into its clinical pipeline and research activities, which is common for early-stage biopharmaceutical companies.
When does ACRS report earnings?
Aclaris Therapeutics reports on a quarterly cadence. Because it is a clinical-stage company, pipeline updates often matter as much as financial results. Check the company's investor relations page for the latest schedule.
Is ACRS a good stock to buy?
The UQS Score rates ACRS as Poor, with Weak readings across Quality, Moat, and Growth pillars. The Risk pillar is the relative strength. Investors should review the full pillar breakdown before drawing conclusions.
Is ACRS overvalued?
UQS rates ACRS's Valuation as Elevated. For a clinical-stage company without product revenue, valuation is inherently tied to pipeline expectations rather than current earnings power.
What is ACRS's market cap bracket?
ACRS is classified as a small-cap stock. Small-cap clinical-stage biotechs typically carry higher volatility and binary risk tied to clinical trial outcomes.
Is ACRS a long-term quality investment?
From a long-term quality perspective, ACRS currently scores Poor on the UQS composite. Weak Moat and Growth pillar ratings suggest the company has not yet established durable competitive advantages or consistent growth. Pipeline success could change this picture over time.
What sector does ACRS belong to?
ACRS belongs to the Healthcare sector, specifically within clinical-stage biopharmaceuticals. The company focuses on immune-inflammatory disease indications, a competitive but high-need therapeutic area.
Unlock Full ACRS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access full financial metrics and trend data
- ✓Compare ACRS against sector peers on a standardized scoring framework
- ✓Get the complete analyst view available to Pro members
Pro Analysis
ACRS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 17.0 | 1.7 | 8.0 | 18.8 | 71.9 | 0.0 | +0.5 |
| May 10, 2026 | 16.5 | 0.0 | 8.0 | 18.8 | 71.9 | 0.0 | -0.4 |
| May 8, 2026 | 16.9 | 1.7 | 8.0 | 18.8 | 71.6 | 0.0 | -0.2 |
| Apr 2, 2026 | 17.1 | 1.7 | 8.0 | 18.8 | 72.8 | 0.0 | — |
ACRS — Pillar Breakdown
Quality
— 1.7/100 (25%)Aclaris Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 18.8/100 (20%)Aclaris Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 71.9/100 (15%)Aclaris Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Aclaris Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 8/100 (25%)Aclaris Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ACRS.
Score Composition
Financial Data
More Stock Analysis
How is the ACRS UQS Score Calculated?
The UQS (Unified Quality Score) for Aclaris Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Aclaris Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Aclaris Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.